Smooth sailing for NeuroDiscovery

By Staff Writers
Tuesday, 22 July, 2008

Perth biotech NeuroDiscovery has successfully completed an early stage trial of its neuropathic pain candidate NSL-043.

The compound, previously developed by another company for inflammatory disease, was successful in single ascending dose clinical trials and has now completed a multiple ascending dose trail.

The company said the compound's adverse event profile demonstrated good safety and tolerability.

NeuroDiscovery is also investigating the development of antagonists of the connexin and pannexin families of gap junction proteins.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd